IP Library Granted Patent US 7,226,998
Granted Patent B2
US 7,226,998 · App. 10/935,532 · Granted Jun 5, 2007

Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,226,998
App. No.
10/935,532
Granted
Jun 5, 2007
Kind
B2
Abstract

Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.

Claims (8)

1. A fusion comprising an immunoglobulin (Ig) moiety linked by a peptide bond to the p35 subunit of interleukin-12 (IL-12), the p35 subunit of IL-12 being linked to the p40 subunit of IL-12.

2. The fusion protein of claim 1 , wherein the Ig moiety comprises a single-chain Fv (scFv) antibody, the scFv antibody comprising an Ig heavy chain variable region and an Ig light chain variable region.

3. The fusion protein of claim 2 , wherein the Ig light chain variable region is N-terminal relative to the Ig heavy chain variable region.

4. The fusion protein of claim 1 , wherein the p35 subunit of IL-12 and the p40 subunit of IL-12 are linked by a disulfide bond.

5. The fusion protein of claim 1 , wherein the p35 subunit of IL-12 is linked to the amino terminus of the Ig moiety.

6. The fusion protein of claim 5 , wherein the p35 subunit of IL-12 is linked to the amino terminus of an Ig heavy chain.

7. The fusion protein of claim 1 , wherein the Ig moiety has antigen-binding specificity.

8. A fusion protein comprising a single-chain Fv (scFv) antibody linked by a peptide bond to the p35 subunit of interleukin-12 (IL-12), the p35 subunit of IL- 12 being linked to the p40 subunit of IL-12, wherein the scFv antibody comprises an Ig heavy chain variable region linked by a linker sequence to an Ig light chain variable region.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2008
From: EMD LEXIGEN RESEARCH CENTER CORP.
To: MERCK PATENT GMBH
Reel/Frame 020451/0956 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2005
From: GILLIES, STEPHEN D.; LO, KIN-MING; LAN, YAN
To: EMD LEXIGEN RESEARCH CENTER CORP.
Reel/Frame 017023/0477 →